.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Long-term results from the Infant Aphakia Treatment Study show that secondary intraocular lens (IOL) implantation is an important part of the treatment pathway for some children who undergo unilateral cataract surgery in infancy. In the reported cohort, a substantial proportion of eyes initially managed with aphakia and contact lenses later received a secondary IOL. The study is clinically useful because it places secondary implantation within a planned developmental context rather than viewing it simply as a rescue procedure. Decisions can be influenced by age, ocular growth, family ability to maintain contact-lens correction, refractive trajectory, visual rehabilitation, and the child's overall ocular status. For pediatric surgeons, timing remains individualized, and the presence of adequate capsular and ciliary support must be considered carefully. Long-term follow-up is essential because visual outcomes are determined not only by the IOL procedure itself but also by amblyopia therapy and sustained optical correction. The publication supports a patient-specific approach in which secondary IOL implantation is considered when the benefits of a more permanent optical solution outweigh the risks of another intraocular procedure.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Long-term results from the Infant Aphakia Treatment Study show that secondary intraocular lens (IOL) implantation is an important part of the treatment pathway for some children who undergo unilateral cataract surgery in infancy. In the reported cohort, a substantial proportion of eyes initially managed with aphakia and contact lenses later received a secondary IOL. The study is clinically useful because it places secondary implantation within a planned developmental context rather than viewing it simply as a rescue procedure. Decisions can be influenced by age, ocular growth, family ability to maintain contact-lens correction, refractive trajectory, visual rehabilitation, and the child's overall ocular status. For pediatric surgeons, timing remains individualized, and the presence of adequate capsular and ciliary support must be considered carefully. Long-term follow-up is essential because visual outcomes are determined not only by the IOL procedure itself but also by amblyopia therapy and sustained optical correction. The publication supports a patient-specific approach in which secondary IOL implantation is considered when the benefits of a more permanent optical solution outweigh the risks of another intraocular procedure.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
